Controlled delivery of nilotinib using LDH/Fe

Milad Gholami, Hori Ghaneialvar, Somayeh Molaei, Naser Abbasi, Ali Aidy, Mahsa Abbasi

Abstract read

In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Milad GholamiBiotechnology and Medicinal Plants Research Center, Ilam University of Medical Sciences, P.O. Box 6939177143, Ilam, Iran.

Hori GhaneialvarBiotechnology and Medicinal Plants Research Center, Ilam University of Medical Sciences, P.O. Box 6939177143, Ilam, Iran. ghaneialvar-h@medilam.ac.ir.

Somayeh MolaeiDepartment of Chemistry, Faculty of Science, Kurdistan University, Sanandaj, Iran.

Naser AbbasiBiotechnology and Medicinal Plants Research Center, Ilam University of Medical Sciences, P.O. Box 6939177143, Ilam, Iran.

Ali AidyBiotechnology and Medicinal Plants Research Center, Ilam University of Medical Sciences, P.O. Box 6939177143, Ilam, Iran.

Mahsa AbbasiDepartment of Chemistry, Basic of Science Faculty, Ilam University, Ilam, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic myeloid leukemia remains a significant challenge in cancer treatment because conventional drug delivery systems often fail to provide sustained release and targeted therapeutic effects. To address these limitations, this study a chitosan-based nanocomposite hydrogel system for the controlled delivery of nilotinib, a tyrosine kinase inhibitor used to treat chronic myeloid leukemia. Fe

Indexed as

ChitosanDrug Delivery SystemsFerric CompoundsHydrogelsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveNanocompositesPyrimidinesAntineoplastic AgentsCell Line, TumorDrug CarriersDrug LiberationHumansL-Lactate DehydrogenaseAntineoplastic AgentsChitosanDrug CarriersFerric Compoundsferric oxideHydrogelsL-Lactate DehydrogenasenilotinibPyrimidinesBiocompatibilityChronic myeloid leukemiaDrug deliveryHydrogel beadsNanocompositeNilotinib

Identifiers

PMID42270788

DOI10.1038/s41598-026-57760-3

PMCPMC13433789

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.